Clinical Trial

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Protocol Amendment History 1 change
notable Trial sites expanded: 15 -> 19 locations 2026-06-19
Trial Details
NCT Number NCT06990880
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms, Prostate
Enrollment 85 participants
Start Date 2025-06-12
Primary Completion 2027-10-26 (estimated)
Study Completion 2028-08-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-18